Long‑term safety of childhood growth hormone treatment:evidences from real‑world study and future directions  

作　　者：Cai Zhang Yan Liang Xiao‑Ping Luo 

机构地区：[1]Department of Pediatrics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,People’s Republic of China [2]Hubei Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases,Wuhan,China

出　　处：《World Journal of Pediatrics》2025年第1期3-7,共5页世界儿科杂志(英文版)

摘　　要：Background Recombinant human GH(rhGH)was first approved to treat children with growth hormone deficiency(GHD)by Food and Drug Administration(FDA)in the United States in 1985.The indications subsequently expanded to growth failure secondary to chronic renal failure,Turner syndrome,Prader‒Willi syndrome,small for gestational age(SGA)without catch-up growth,idiopathic short stature(ISS),SHOX deficiency,Noonan syndrome and so on[1].The efficacy and the safety of rhGH have been proven in randomized controlled trials(RCTs),which are considered the highest level of evidences in clinical practice.However,due to the strict criteria and short observational time,RCTs could not fully reflect the reality of rhGH,especially in terms of safety[2].

关 键 词：growth failure recombinant human GH childhood growth hormone treatment growth hormone deficiency ghd real world study growth hormone deficiency randomized controlled tria chronic renal failureturner 

分 类 号：R725.8[医药卫生—儿科]